Features of lipid profile in multiple myeloma patients
DOI:
https://doi.org/10.34687/2219-8202.JAD.2023.04.0005Keywords:
multiple myeloma, lipids, anticancer therapy.Abstract
Abstract. Currently, cardiovascular and oncological diseases have the highest morbidity and mortality in the world. It is known that 34.8% of cancer patients die from non-cancer causes. In their structure, 33% is occupied by cardiovascular diseases (CVD). It is also known that CVD is responsible for 15-20% of deaths in the group of patients with multiple myeloma. For this reason, it seems interesting to study the risk factors for the development and/or progression of CVD in patients with newly diagnosed multiple myeloma (MM) before and during anticancer therapy, using the example of studying the lipid profile in this patient population.
The aim of this study is to evaluate the parameters of the lipid profile in patients with MM before the start of treatment and during antitumor therapy according to the VCD scheme.
Materials and Methods: The study included 43 patients (20 men and 23 women, median age 60 years) with newly diagnosed Durie-Salmon stage IIA multiple myeloma in combination with grade 1 arterial hypertension, who made up group A. Group B included 46 patients with arterial hypertension of the 1st degree.
Conclusion. Patients with MM prior to anticancer therapy are characterized by lower concentrations of total cholesterol and high-density lipoproteins relative to the group of patients without MM. However, during therapy according to the VCD regimen, which includes bortezomib, cyclophosphamide, and dexamethasone, an increase in all lipid profile parameters is observed.
Downloads
References
Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. SHahzadovoj The state of oncological care for the population of Russia in 2021. − M.: MNIOI im. P.A. Gercena − filial FGBU «NMIC radiologii» Minzdrava Rossii, 2022. − ill. – 239 s. Russian. (Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Состояние онкологической помощи населению России в 2021 году. − М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. − илл. – 239 с.)
Agmon Nardi I, Iakobishvili Z. Cardiovascular Risk in Cancer Survivors. Curr Treat Options Cardiovasc Med. 2018;20(6):47. Published 2018 Apr 28. doi:10.1007/s11936-018-0645-8
Cowan AJ, Green DJ, Kwok M, Lee S., Coffey D. G., Holmberg L. A, et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464-477. doi:10.1001/jama.2022.0003
McQuilten Z, Wellard C, Moore E, Augustson B., Bergin K., Blacklock H, et al. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Br J Haematol. 2022;198(5):830-837. doi:10.1111/bjh.18324
Schoenbeck KL, Fiala MA, Wildes TM. Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. J Geriatr Oncol. 2021;12(7):1005-1009. doi:10.1016/j.jgo.2021.02.009
Coombes EJ, Shakespeare PG, Batstone GF. Lipoprotein changes after burn injury in man. J Trauma. 1980;20(11):971-975. doi:10.1097/00005373-198011000-00012
Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732-749. doi:10.1038/nrc.2016.89
Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606. doi:10.1084/jem.20201606
Fairfield H, Costa S, Falank C, Farrell M, Murphy CS, D'Amico A, et al. Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes. Front Oncol. 2021;10:584683. Published 2021 Feb 18. doi:10.3389/fonc.2020.584683
Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21(5):1079-1088. doi:10.1038/sj.leu.2404621
Soran H, Ho JH, Durrington PN. Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets. Curr Opin Lipidol. 2018;29(4):318-326. doi:10.1097/MOL.0000000000000526
Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z. Cholesterol levels in patients with multiple myeloma. Ann Hematol. 2008;87(3):223-228. doi:10.1007/s00277-007-0375-6
Heckmann MB, Doroudgar S, Katus HA, Lehmann LH. Cardiovascular adverse events in multiple myeloma patients. J Thorac Dis. 2018;10(Suppl 35):S4296-S4305. doi:10.21037/jtd.2018.09.87
Khan W, Augustine D, Rao RS, Patil S, Awan KH, Sowmya SV, et al. Lipid metabolism in cancer: A systematic review. J Carcinog. 2021;20:4. Published 2021 May 6. doi:10.4103/jcar.JCar_15_20
Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527-2533. doi:10.1210/jc.2002-021558
Lupoli R, Ambrosino P, Tortora A, Barba L, Lupoli GA, Di Minno MN. Markers of atherosclerosis in patients with Cushing's syndrome: a meta-analysis of literature studies. Ann Med. 2017;49(3):206-216. doi:10.1080/07853890.2016.1252055
MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers?. Int J Mol Sci. 2021;22(14):7622. Published 2021 Jul 16. doi:10.3390/ijms22147622
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Е. В. Самойлова, Т. П. Миронова, И. Л. Давыдкин, А. С. Сустретов, Т. Ю. Степанова, К. В. Наумова
This work is licensed under a Creative Commons Attribution 4.0 International License.
